For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Phase 1/2, First-In-Human, Open-Label, Dose-Escalation Study Of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone And In Combination With Mga012 (Anti–PD-1 Antibody) In Patients With Advanced Solid Tumors
To evaluate the safety and effectiveness of the test drug, MGC018.
DiagnosisPatients who have a locally advanced or metastatic solid tumor that has progressed during or after standard treatments.
Patients with histologically proven, relapsed or refractory, unresectable locally advanced or metastatic solid tumors.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
In this study, patients will receive the test drug, MGC018 alone or MGC018 in a combination with another drug called MGA012.
For more information, visit ClinicalTrials.gov